India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals

 
• By Anju Ghangurde
  
Diabetes
PATIENT DATA PERTAINING TO SGLT2 INHIBITORS ARE TO BE EXAMINED IN INDIA

More from Drug Safety

More from Pink Sheet